NasdaqGS - Delayed Quote • USD
Alkermes plc (ALKS)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | 0.6 | 0.74 | 2.76 | 2.58 |
| Low Estimate | 0.53 | 0.68 | 2.49 | 2.03 |
| High Estimate | 0.68 | 0.8 | 2.9 | 3.16 |
| Year Ago EPS | 0.01 | 0.55 | 1.44 | 2.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 12 | 12 |
| Avg. Estimate | 362.62M | 389.74M | 1.52B | 1.52B |
| Low Estimate | 347.93M | 379.17M | 1.46B | 1.43B |
| High Estimate | 374.7M | 395.79M | 1.56B | 1.74B |
| Year Ago Sales | 287.6M | 617.4M | 1.66B | 1.52B |
| Sales Growth (year/est) | 26.10% | -36.90% | -8.70% | 0.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.01 | 0.46 | 0.44 | 0.51 |
| EPS Actual | 0.01 | 0.55 | 0.64 | 0.22 |
| Difference | 0.02 | 0.09 | 0.2 | -0.29 |
| Surprise % | 200.00% | 19.60% | 45.50% | -56.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.6 | 0.74 | 2.76 | 2.58 |
| 7 Days Ago | 0.62 | 0.76 | 2.79 | 2.68 |
| 30 Days Ago | 0.69 | 0.79 | 2.73 | 2.7 |
| 60 Days Ago | 0.69 | 0.79 | 2.79 | 2.7 |
| 90 Days Ago | 0.49 | 0.56 | 2.29 | 2.51 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | ALKS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5,900.00% | -- | -- | 2.60% |
| Next Qtr. | 34.50% | -- | -- | 13.40% |
| Current Year | 91.70% | -- | -- | 5.20% |
| Next Year | -6.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 24.80% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 3.24% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 4/19/2024 |
| Maintains | Jefferies: Buy to Buy | 4/9/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 4/1/2024 |
| Initiated | Baird: Outperform | 3/19/2024 |
| Downgrade | UBS: Neutral to Sell | 2/20/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/16/2024 |
Related Tickers
IRWD Ironwood Pharmaceuticals, Inc.
8.08
-0.25%
NBIX Neurocrine Biosciences, Inc.
137.76
-0.87%
COLL Collegium Pharmaceutical, Inc.
35.84
+1.01%
ITCI Intra-Cellular Therapies, Inc.
72.13
-1.35%
SUPN Supernus Pharmaceuticals, Inc.
29.31
-3.14%
EGRX Eagle Pharmaceuticals, Inc.
4.2400
-6.81%
AMPH Amphastar Pharmaceuticals, Inc.
40.83
-0.41%
LFCR Lifecore Biomedical, Inc.
6.64
+4.90%
DCPH Deciphera Pharmaceuticals, Inc.
14.18
-3.01%
HCM HUTCHMED (China) Limited
18.99
+3.15%